BioSpace News Archive

Takeda Pharmaceutical’s Alunbrig (brigatinib) hit its Phase III primary endpoints of statistically significant improvement in progression-free survival compared to crizotinib (Pfizer’s Xalkori) in a subset of lung cancer patients following the first pre-specified interim analysis.

Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.

Boston-based resTORbio, which was spun out of Novartis in April 2017, announced positive topline results from its Phase IIb clinical trial of RTB101 in patients with respiratory tract infections (RTIs).

After multiple suspensions, the U.S. House of Representatives overwhelmingly voted to repeal a 2.3 percent tax on medical devices that was part of the Affordable Care Act that industry representatives believed stifled innovation.

Since taking over the helm of GlaxoSmithKline, Emma Walmsley has been driving changes at the company with a heavy focus on pharma R&D. Today, Walmsley and R&D Head Hal Barron unveiled a long-term plan for R&D that is focused on the immune system and genetics.

South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.

Excluding the impact of ASC 606, record net business wins in the quarter of $600 million; a book to bill of 1.27.

Multi-protein diagnostic test with 98 percent accuracy published in official journal of the American Society for Preventive Cardiology

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), met a primary endpoint of overall survival (OS) as monotherapy in patients whose tumors expressed PD-L1 (Combined Proportion Score (CPS) ≥20).

Summary Judgment Ruling Affirms Method Claims Covering 1.5kHz to 100kHz Frequency Range